Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for ew
May 22 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 78.12 - 150.41
Open     -
Vol / Avg. 0.00/1.19M
Mkt cap 14.08B
P/E 16.20
Div/yield     -
EPS 8.08
Shares 107.56M
Beta 0.61
Inst. own 87%
Jul 27, 2015
Q2 2015 Edwards Lifesciences Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 10, 2015
Edwards Lifesciences Corp at Goldman Sachs Healthcare Conference - 5:00PM EDT - Add to calendar
May 28, 2015
Edwards Lifesciences Corp at Sanford C Bernstein Strategic Decisions Conference - 2:00PM EDT - Add to calendar
May 14, 2015
Edwards Lifesciences Corp Annual Shareholders Meeting - Webcast
May 8, 2015
Edwards Lifesciences Corp Annual Shareholders Meeting (Estimated)
Apr 23, 2015
Q1 2015 Edwards Lifesciences Corp Earnings Call - Webcast
Apr 23, 2015
Q1 2015 Edwards Lifesciences Corp Earnings Release
Mar 15, 2015
Edwards Lifesciences Corp at American College of Cardiology (ACC) Expo Analyst Update
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 20.90% 34.92%
Operating margin 27.53% 49.25%
EBITD margin - 23.96%
Return on average assets 14.12% 26.02%
Return on average equity 22.47% 43.42%
Employees 9,100 -
CDP Score - -


1 Edwards Way
IRVINE, CA 92614-5688
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. Cardiovascular disease is the primary cause of death in the world, and is the top disease in terms of health care spending in nearly every country. Cardiovascular disease is progressive in that it tends to worsen over time and often affects an individual's entire circulatory system. The products and technologies provided by Edwards Lifesciences are categorized as Surgical Heart Valve Therapy, combining surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 48
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 53
Bio & Compensation  - Reuters
Catherine M. Szyman Corporate Vice President, Critical Care
Age: 48
Bio & Compensation  - Reuters
Patrick B. Verguet Corporate Vice President, Europe, Middle East and Africa
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Huimin Wang M.D. Corporate Vice President, Japan, Asia Pacific
Age: 58
Bio & Compensation  - Reuters
Larry L. Wood Corporate Vice President - Transcatheter Heart Valve Therapy
Age: 49
Bio & Compensation  - Reuters
John T. Cardis Independent Director
Age: 73
Bio & Compensation  - Reuters
Kieran T. Gallahue Independent Director
Age: 51
Bio & Compensation  - Reuters
Robert A. Ingram Independent Director
Age: 72
Bio & Compensation  - Reuters